Treatment of Brucellosis in Pregnancy
For pregnant women with brucellosis, use rifampicin 600-900 mg daily combined with trimethoprim-sulfamethoxazole (TMP-SMX) 800/160 mg twice daily for 6 weeks as the primary regimen, avoiding tetracyclines due to fetal toxicity.
Rationale for Pregnancy-Specific Treatment
The standard brucellosis regimens recommended by WHO and the Ioannina guidelines 1 rely heavily on doxycycline, which is contraindicated in pregnancy due to risks of permanent tooth discoloration and impaired bone development in the fetus. This necessitates alternative approaches that balance maternal efficacy with fetal safety.
Recommended Treatment Regimen
First-Line: Rifampicin + TMP-SMX
- Rifampicin: 600-900 mg once daily for 6 weeks
- TMP-SMX: 800/160 mg twice daily for 6 weeks
This combination is the most frequently used regimen in pregnant women based on available evidence 2, 3, 4. A systematic review found adverse obstetric outcomes occurred in 16% of cases with this regimen 2, which represents acceptable risk given the serious complications of untreated brucellosis in pregnancy.
Alternative Considerations for Complicated Cases
For severe or complicated brucellosis (neurobrucellosis, osteoarticular involvement):
- Add ceftriaxone to the rifampicin-TMP-SMX combination 5, 3
- Consider gentamicin 5 mg/kg daily for 7 days in the first trimester when aminoglycoside risks are lower 5
Critical Timing Considerations
Early treatment initiation is paramount 5. Antepartum antimicrobial therapy significantly reduces abortion risk compared to no treatment or delayed treatment 6. The overall success rate with appropriate therapy during pregnancy approaches 90% for normal delivery 6.
Obstetric Outcomes and Monitoring
Even with treatment, be prepared for:
- Abortion risk: 23.3% overall in treated cases 2
- Preterm birth: Occurs in a subset of cases
- Low birth weight: Monitor fetal growth
- Recurrence: Only 3% with adequate treatment 2
The abortion rate in humans is lower than in animals due to absence of erythritol in human placenta and anti-brucella activity in amniotic fluid 6.
Common Pitfalls to Avoid
- Do not use doxycycline - Despite being first-line in non-pregnant adults 1, tetracyclines cause fetal harm
- Do not delay treatment - Waiting for culture confirmation (which takes weeks) increases abortion risk
- Avoid inadequate duration - Full 6-week course is essential; shorter courses increase relapse risk 3
- Do not miss follow-up - Patients who interrupt therapy or miss follow-ups have higher relapse rates 3
Postpartum Management
After delivery, consider switching to standard doxycycline-based regimens if:
- The patient is not breastfeeding
- Treatment response was suboptimal
- Complicated disease requires extended therapy
One case report successfully used doxycycline + ceftriaxone postpartum with instruction not to breastfeed 5.
Evidence Quality Note
The evidence for pregnancy-specific treatment is limited to retrospective studies and case series 2. No randomized controlled trials exist for this population. The recommendations represent consensus based on safety profiles of available antibiotics and observational data showing rifampicin-TMP-SMX as the most commonly used and reasonably effective combination 2, 3, 4.